|
Tuesday, 21 June 2022, 23:45 HKT/SGT | |
| |
|
|
Gaithersburg, MD, USA and Suzhou BioBay, China, June 21, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer, Dmitry Samarsky, PhD, will present the latest developments and expanded applications of its Dual-Targeted RNAi therapeutics based on its proprietary GalAhead(TM) technology and product pipeline, at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium. The Symposium will take place virtually on June 22-24, 2022.
Sirnaomics' proprietary GalNAc-RNAi therapeutic platform, GalAhead(TM), relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA(TM) (miniaturized RNAi triggers) and muRNA(TM) (multi-unit RNAi triggers). mxRNAs(TM) are comprised of single ~30 nt long oligonucleotides to downregulate individual genes, while muRNA(TM) molecules are comprised of multiple oligonucleotides to silence two or more targets simultaneously. Sirnaomics will present data at the Symposium evaluating these two technologies, especially the muRNA molecule that has been validated in an animal model for its dual-targeted gene silencing activity, and a progress report on the quickly expanding GalAhead(TM) therapeutic pipeline.
Presentation Details -- Presentation Title: GalAhead(TM): a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes -- Presenter: Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics -- Date: June 22-24, 2022 (The presentation will be pre-recorded and available on demand) -- Location: Online via the Symposium website
"Sirnaomics is striving to develop RNAi delivery technology for effective therapeutic application. Our novel GalAhead(TM) technology has been repeatedly validated with both single-targeted and dual-targeted RNAi therapeutics using rodents and non-human primate animal models," said Dr. Patrick Lu, founder, chairman of the Board, Executive Director, President and CEO of Sirnaomics. "We are expecting expanded clinical testing for our GalAhead(TM) platform and RNAi drug candidates for several liver metabolic diseases in 2023."
"Since we introduced GalAhead(TM) in 2019, the technology has continuously proved to be both robust and reproducible," said Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics. "Based on this progress, we will have our first therapeutic candidate filed for IND approval by the end of 2022. This year, we have already nominated four more GalAhead(TM) based developmental candidates, including the first double-targeting molecule, and are planning to add more by the end of the year."
For more information about Sirnaomics' presentation, please visit the event website at https://www.umassmed.edu/RNATx/.
About Sirnaomics Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at www.sirnaomics.com.
CONTACT: Dmitry Samarsky, PhD Chief Technology Officer, Sirnaomics Email: DmitrySamarsky@sirnaomics.com
Investor Relations: Nigel Yip Chief Financial Officer, China, Sirnaomics Email: NigelYip@sirnaomics.com
US Media Contact: Alexis Feinberg Tel: +1 203 939 2225 Email: Alexis.Feinberg@westwicke.com
Asia Media Contact: Bunny Lee Tel: +852 3150 6707 Email: sirnaomics.hk@pordahavas.com
Topic: Press release summary
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Thursday, March 28, 2024 3:45:00 PM
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 15:26 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT/SGT
|
|
|
Turning Loss into Profit in 2023: IGG Achieved over HK$430 million in 2H23
Mar 28, 2024 14:25 HKT/SGT
|
|
|
Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan
Thursday, March 28, 2024 12:52:00 PM
|
|
|
Toyota Releases Sales, Production, and Export Results for February 2024
Thursday, March 28, 2024 12:35:00 PM
|
|
|
Steady Growth and Enhanced Value: Sunshine Insurance's 'New Sunshine Strategy' Sets Sail
Mar 28, 2024 12:33 HKT/SGT
|
|
|
Annual hiring demand declines 22% in Singapore: foundit Insights Tracker
Mar 28, 2024 11:10 HKT/SGT
|
|
|
Philippines Achieves Record-Breaking 18% Annual Surge in Hiring Activity for February 2024: foundit Insights Tracker
Mar 28, 2024 11:10 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|